Citigroup Inc Arcellx, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Citigroup Inc holds 43,154 shares of ACLX stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,154

Previous 21,892 97.12%

Holding current value

$3.26 Million

Previous $1.21 Million 198.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$50.91 - $86.61 $1.08 Million - $1.84 Million	21,262 Added 97.12%	43,154 $3.6 Million
Q2 2024 Aug 12, 2024	SELL	$49.74 - $66.98 $4.63 Million - $6.23 Million	-93,055 Reduced 80.95%	21,892 $1.21 Million
Q1 2024 May 10, 2024	BUY	$51.85 - $73.49 $3.25 Million - $4.6 Million	62,616 Added 119.65%	114,947 $7.99 Million
Q4 2023 Feb 09, 2024	SELL	$31.75 - $57.99 $529,748 - $967,563	-16,685 Reduced 24.18%	52,331 $2.9 Million
Q3 2023 Nov 09, 2023	BUY	$31.51 - $37.4 $177,023 - $210,113	5,618 Added 8.86%	69,016 $2.48 Million
Q2 2023 Aug 10, 2023	SELL	$27.49 - $46.9 $1.38 Million - $2.35 Million	-50,205 Reduced 44.19%	63,398 $2 Million
Q1 2023 May 11, 2023	BUY	$26.92 - $33.94 $1.73 Million - $2.18 Million	64,275 Added 130.3%	113,603 $3.5 Million
Q4 2022 Feb 09, 2023	SELL	$17.18 - $33.0 $600,166 - $1.15 Million	-34,934 Reduced 41.46%	49,328 $1.53 Million
Q3 2022 Nov 10, 2022	SELL	$16.67 - $22.04 $527,255 - $697,103	-31,629 Reduced 27.29%	84,262 $1.58 Million
Q2 2022 Aug 10, 2022	BUY	$7.21 - $24.43 $822,206 - $2.79 Million	114,037 Added 6150.86%	115,891 $2.1 Million
Q1 2022 May 12, 2022	BUY	$12.97 - $19.14 $24,046 - $35,485	1,854 New	1,854 $26,000

Others Institutions Holding ACLX

# of Institutions

204

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.31B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account